Author's reply to Flecainide and propafenone: good twins for premature ventricular contractions' killing but not exactly superimposable

We thank Capucci and colleagues for their thoughtful comments. We agree that mean doses of flecainide (88.5 ± 11.3 mg twice daily) and propafenone (extended-release 291.7 ± 19.5 mg twice daily, 1 patient immediate-release 150 mg three times daily) were low. Despite this, mean premature ventricular contraction (PVC) burden decreased by more than 72%. It is possible that higher doses of class 1C anti-arrh ythmic drugs would have resulted in even greater efficacy. Capucci and colleagues also make an important point regarding the high rate of concomitant beta blocker use (90%).
Source: Heart Rhythm - Category: Cardiology Authors: Source Type: research